Abstract Oestrogen receptor-positive (ER+) breast cancer is a major cause of cancer death
in women. Although aromatase inhibitors suppress the function of ER and reduce the risk of …

Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin
(mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition …

Approximately 80% of breast cancers (BC) are estrogen receptor (ER)-positive and thus
endocrine therapy (ET) should be considered complementary to surgery in the majority of …

The present review discusses recent work on melatonin-mediated circadian regulation, the
metabolic and molecular signaling mechanisms that are involved in human breast cancer …

Hormone-receptor-positive breast cancer accounts for the majority—up to 80%—of all breast
cancers. The evolution of breast cancer from early stage to the metastatic setting leads to …

Hormone receptor positive tumors represent the most common form of breast cancer and
account for most of the deaths from the disease. Endocrine therapy represents the main …

Abstract The PI3K/Akt/mTOR (phosphatidylinositol 3 kinase/Akt/mammalian target of
rapamycin) signalling pathway is an established driver of oncogenic activity in human …

The androgen receptor (AR) is expressed in the majority of breast cancer and across the
three main breast cancer subtypes. Historically, the oncogenic role of AR has best been …

Estrogen receptor (ER) is expressed in approximately 70% of newly diagnosed breast
tumors. Although endocrine therapy targeting ER is highly effective, intrinsic or acquired …

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has
brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have …